The global biosimulation market is experiencing rapid growth, poised to reach a valuation of USD 8.65 billion by 2030, expanding at a robust CAGR of 15.8% during the forecast period. This surge is attributed to the growing need for cost-effective drug development, rising acceptance of biosimulation in regulatory approvals, and increasing focus on personalized medicine. Biosimulation,...